DexCom Inc. (DXCM) stock forecast and price target
Price $83.33 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($83.33)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $2.70 | +29.2% | $5.2B |
| Next fiscal year ends December 31, 2027 | $3.13 | +16.1% | $5.8B |
| Next quarter ends December 31, 2026 | $0.72 | +5.4% | $1.4B |
| Quarter after ends March 31, 2027 | $0.64 | +13.8% | $1.3B |
Consensus of the analysts covering DexCom, updated daily. In the last 30 days 20 estimates were raised and 2 lowered.
Our model vs. Wall Street
Analysts see 18.3% upside over 12 months. Our discounted cash flow model with moderate assumptions puts DexCom’s intrinsic value about 41% below today’s market value, and it scores 3.4 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the DexCom stock price target?
The average 12-month target from 26 analysts is $98.58, 18.3% above the current price of $83.33 Targets range from $79.00 to $120.00.
Is DexCom a buy according to analysts?
The consensus rating is “Strong buy” (4 strong buy, 22 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is DexCom expected to earn?
Analysts expect EPS of $2.70 for the fiscal year ending December 31, 2026 and $3.13 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.